Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Assets (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Current Assets for 11 consecutive years, with $129.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 40.32% to $129.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $129.3 million, a 40.32% decrease, with the full-year FY2025 number at $129.3 million, down 40.32% from a year prior.
  • Current Assets was $129.3 million for Q4 2025 at Cartesian Therapeutics, down from $147.3 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $229.1 million in Q3 2024 to a low of $89.9 million in Q3 2023.
  • A 5-year average of $149.2 million and a median of $147.7 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 173.23% in 2021, then plummeted 43.72% in 2023.
  • Cartesian Therapeutics' Current Assets stood at $144.4 million in 2021, then rose by 2.56% to $148.1 million in 2022, then plummeted by 38.75% to $90.7 million in 2023, then surged by 138.76% to $216.6 million in 2024, then plummeted by 40.32% to $129.3 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Current Assets are $129.3 million (Q4 2025), $147.3 million (Q3 2025), and $163.4 million (Q2 2025).